Contineum Therapeutics cut to neutral by Baird; price target lowered to $14 from $19
CTNM•Baird cut its rating on Contineum Therapeutics to neutral and lowered its price target to $14 from $19.
Related News
Meta challenges UK online safety watchdog over how fees and fines are calculated
META•
Luda Technology signs MOU to evaluate acquisition of Mongolia Jonsh Tolgoi fluorspar mining rights
LUD•
BioLargo subsidiary Clyra Medical exhibits ViaCLYR wound irrigation solution at SAWC Fall 2026
BLGO•
Goldman Sachs beats quarterly profit estimates on equities strength
GS•
Apple unveils new smart home products, showcasing updated Siri AI
AAPL•